Biogen pays $560m for an unproven Parkinson’s mechanism
All the attention is on aducanumab, but yesterday’s deal with Denali is a reminder that Biogen has other irons in the fire.
Teladoc bets $18.5bn that Covid-19 will change the world for good
The purchase of Livongo is the richest healthcare deal this year, but questions about reimbursement, competition and profitability remain.
Novavax claims its place in Covid-19 vaccine race
Encouraging immune responses and a competitive safety profile in a small trial seem to make Novavax’s vaccine a contender.
The UK bets on Nanopore and Nudge for rapid Covid-19 tests
Fast tests for Covid-19 infections could be very useful – but only if they are accurate.
Healthineers makes its ambition plain with $16.4bn Varian buy
Suddenly 2020’s medtech M&A landscape looks very different.
The Cymabay recovery continues
Encouraging cholangitis data follows the lifting of a clinical hold on Cymabay’s seladelpar, signalling a way forward for a project that looked finished.
Warp Speed keeps on giving
The latest Covid-19 vaccine award sees Glaxo and Sanofi score a $2.1bn windfall from the US government.
Astra shakes things up with Covid-19 pricing disclosure
By signalling that its Covid-19 vaccine could cost just a few dollars Astra could seriously embarrass its competition.
